56F Stock Overview
A clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
EXACT Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 0.48 |
| 52 Week High | NOK 1.09 |
| 52 Week Low | NOK 0.38 |
| Beta | 0.16 |
| 11 Month Change | 1.26% |
| 3 Month Change | -6.02% |
| 1 Year Change | -53.46% |
| 33 Year Change | -65.43% |
| 5 Year Change | n/a |
| Change since IPO | -79.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 56F | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -0.7% | 0.2% |
| 1Y | -53.5% | -17.2% | 8.5% |
Return vs Industry: 56F underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 56F underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 56F volatility | |
|---|---|
| 56F Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 56F's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 56F's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 12 | Per Walday | exact-tx.com |
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy.
EXACT Therapeutics AS Fundamentals Summary
| 56F fundamental statistics | |
|---|---|
| Market cap | €15.85m |
| Earnings (TTM) | -€4.75m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.3x
P/E RatioIs 56F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 56F income statement (TTM) | |
|---|---|
| Revenue | NOK 0 |
| Cost of Revenue | NOK 0 |
| Gross Profit | NOK 0 |
| Other Expenses | NOK 54.84m |
| Earnings | -NOK 54.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 56F perform over the long term?
See historical performance and comparison